Exagen Statistics
Total Valuation
Exagen has a market cap or net worth of $80.36 million. The enterprise value is $81.69 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Exagen has 17.90 million shares outstanding. The number of shares has increased by 2.96% in one year.
| Current Share Class | 17.90M |
| Shares Outstanding | 17.90M |
| Shares Change (YoY) | +2.96% |
| Shares Change (QoQ) | +0.95% |
| Owned by Insiders (%) | 10.10% |
| Owned by Institutions (%) | 29.92% |
| Float | 9.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.47 |
| Forward PS | 1.20 |
| PB Ratio | 8.30 |
| P/TBV Ratio | 8.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.70, with a Debt / Equity ratio of 2.45.
| Current Ratio | 2.70 |
| Quick Ratio | 2.21 |
| Debt / Equity | 2.45 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.10 |
Financial Efficiency
Return on equity (ROE) is -93.78% and return on invested capital (ROIC) is -21.39%.
| Return on Equity (ROE) | -93.78% |
| Return on Assets (ROA) | -16.77% |
| Return on Invested Capital (ROIC) | -21.39% |
| Return on Capital Employed (ROCE) | -43.73% |
| Revenue Per Employee | $258,795 |
| Profits Per Employee | -$70,302 |
| Employee Count | 215 |
| Asset Turnover | 1.09 |
| Inventory Turnover | 5.24 |
Taxes
In the past 12 months, Exagen has paid $12,000 in taxes.
| Income Tax | 12,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +213.02% in the last 52 weeks. The beta is 1.46, so Exagen's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | +213.02% |
| 50-Day Moving Average | 3.91 |
| 200-Day Moving Average | 3.38 |
| Relative Strength Index (RSI) | 58.40 |
| Average Volume (20 Days) | 118,553 |
Short Selling Information
The latest short interest is 46,157, so 0.26% of the outstanding shares have been sold short.
| Short Interest | 46,157 |
| Short Previous Month | 17,571 |
| Short % of Shares Out | 0.26% |
| Short % of Float | 0.50% |
| Short Ratio (days to cover) | 0.45 |
Income Statement
In the last 12 months, Exagen had revenue of $55.64 million and -$15.12 million in losses. Loss per share was -$0.83.
| Revenue | 55.64M |
| Gross Profit | 33.11M |
| Operating Income | -13.64M |
| Pretax Income | -17.28M |
| Net Income | -15.12M |
| EBITDA | -11.91M |
| EBIT | -13.64M |
| Loss Per Share | -$0.83 |
Full Income StatementBalance Sheet
The company has $22.04 million in cash and $23.36 million in debt, giving a net cash position of -$1.33 million or -$0.07 per share.
| Cash & Cash Equivalents | 22.04M |
| Total Debt | 23.36M |
| Net Cash | -1.33M |
| Net Cash Per Share | -$0.07 |
| Equity (Book Value) | 9.54M |
| Book Value Per Share | 0.54 |
| Working Capital | 22.95M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.28 million and capital expenditures -$515,000, giving a free cash flow of -$13.79 million.
| Operating Cash Flow | -13.28M |
| Capital Expenditures | -515,000 |
| Free Cash Flow | -13.79M |
| FCF Per Share | -$0.77 |
Full Cash Flow StatementMargins
Gross margin is 59.51%, with operating and profit margins of -24.51% and -27.17%.
| Gross Margin | 59.51% |
| Operating Margin | -24.51% |
| Pretax Margin | -27.14% |
| Profit Margin | -27.17% |
| EBITDA Margin | -21.41% |
| EBIT Margin | -24.51% |
| FCF Margin | n/a |
Dividends & Yields
Exagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.96% |
| Shareholder Yield | n/a |
| Earnings Yield | -18.81% |
| FCF Yield | -17.16% |
Analyst Forecast
The average price target for Exagen is $7.50, which is 66.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.50 |
| Price Target Difference | 66.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 13.87% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Exagen has an Altman Z-Score of -7.63 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.63 |
| Piotroski F-Score | 3 |